Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -262.64% is 795% below its 5-year average of -29.34%, near the low end of its 5-year range (-262.64%–-19.03%).
As of the fiscal period ended Tuesday, June 30, 2026. 123.22% below its 12-month average of -117.66%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -262.64%.
RETURN ON EQUITY (ROE)
-262.64%
RETURN ON EQUITY (ROE) AVG TTM
-117.66%
RETURN ON EQUITY (ROE) AVG 3Y
-27.79%
RETURN ON EQUITY (ROE) AVG 5Y
-29.34%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-123.22%
CURRENT VS 3Y AVG
-845.07%
CURRENT VS 5Y AVG
-795.30%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-41.15%
median of 712 covered companies
CURRENT VS SECTOR MEDIAN
-538.26%
vs the sector median at left
Health Catalyst, Inc.
Market Cap
$132.64M
Return on Equity (ROE)
-262.64%
TTM Avg
-117.66%
3Y Avg
-27.79%
5Y Avg
-29.34%
Market Cap
$133.72M
Return on Equity (ROE)
-266.86%
TTM Avg
156.76%
3Y Avg
98.17%
5Y Avg
-694.29%
Market Cap
$133.33M
Return on Equity (ROE)
-11.20%
TTM Avg
-11.86%
3Y Avg
-12.45%
5Y Avg
-5.17%
Market Cap
$133.76M
Return on Equity (ROE)
15.55%
TTM Avg
-9.97%
3Y Avg
-34.81%
5Y Avg
-26.89%
Market Cap
$130.78M
Return on Equity (ROE)
-775.59%
TTM Avg
-106.56%
3Y Avg
-86.72%
5Y Avg
-48.99%
Market Cap
$135.65M
Return on Equity (ROE)
-43.42%
TTM Avg
-36.99%
3Y Avg
-36.99%
5Y Avg
-36.99%
Market Cap
$136.91M
Return on Equity (ROE)
-10.08%
TTM Avg
-25.77%
3Y Avg
-36.68%
5Y Avg
-27.09%
Market Cap
$138.31M
Return on Equity (ROE)
-44.26%
TTM Avg
-34.18%
3Y Avg
285.39%
5Y Avg
-5868.11%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Health Catalyst, Inc. (HCAT) | $132.64M | -262.64% | -117.66% | -27.79% | -29.34% |
| LifeMD, Inc. (LFMD)vs › | $133.72M | -266.86% | 156.76% | 98.17% | -694.29% |
| AirSculpt Technologies, Inc. (AIRS)vs › | $133.33M | -11.20% | -11.86% | -12.45% | -5.17% |
| Organigram Global Inc. (OGI)vs › | $133.76M | 15.55% | -9.97% | -34.81% | -26.89% |
| Pyxis Oncology, Inc. (PYXS)vs › | $130.78M | -775.59% | -106.56% | -86.72% | -48.99% |
| Freenome, Inc. (FRNM)vs › | $135.08M | N/A | N/A | N/A | N/A |
| Atrium Therapeutics, Inc. (RNA)vs › | $135.65M | -43.42% | -36.99% | -36.99% | -36.99% |
| KORU Medical Systems, Inc. (KRMD)vs › | $136.91M | -10.08% | -25.77% | -36.68% | -27.09% |
| Alpha Cognition Inc (ACOG)vs › | $138.31M | -44.26% | -34.18% | 285.39% | -5868.11% |
| NRx Pharmaceuticals, Inc. (NRXP)vs › | $125.77M | N/A | 143.89% | 2.05% | -53.47% |
ROE
-262.6%
ROA
-73.8%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -262.64% |
| 2026-03-31 | -192.01% |
| 2025-12-31 | -72.41% |
| 2025-09-30 | -32.42% |
| 2025-06-30 | -28.81% |
| 2025-03-31 | -19.28% |
| 2024-12-31 | -19.03% |
| 2024-09-30 | -22.29% |
| 2024-06-30 | -24.21% |
| 2024-03-31 | -29.55% |
| 2023-12-31 | -32.20% |
| 2023-09-30 | -32.33% |
| 2023-06-30 | -37.79% |
| 2023-03-31 | -36.56% |
| 2022-12-31 | -32.33% |
| 2022-09-30 | -34.23% |
| 2022-06-30 | -30.89% |
| 2022-03-31 | -30.63% |
| 2021-12-31 | -29.35% |
| 2021-09-30 | -26.81% |
| 2021-06-30 | -48.77% |
| 2021-03-31 | -46.83% |
| 2020-12-31 | -41.66% |
| 2020-09-30 | -28.79% |
| 2020-06-30 | -34.35% |
| 2020-03-31 | -31.29% |
| 2019-12-31 | -29.95% |
| 2019-09-30 | -28.76% |
| 2019-03-31 | -176.88% |
